Aura Biosciences, Inc. (AURA) stock

Add to watchlist

Add holding +

NASDAQ: AURA Nasdaq Biotechnology Next results ~November 12, 2026

Aura Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Insiders0 buying, 7 selling0 purchases and 11 sales by directors and officers, last 12 monthsInsider trades
Funds94 adding, 41 cuttingOf 34 active managers that changed their stake, 22 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Current signal Share count rising (dilution): Diluted shares outstanding rose 42.3% year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Aura Biosciences, Inc.'s latest figures clears our strength thresholds.

Things to watch

Results due soon. Results are expected around 10 November; the share price can move sharply on the day.
Share dilution. Diluted shares rose 42.3% in a year.
Volatile shares. Over the past year the shares showed annualised volatility of 56% and a beta of 1.0 against the S&P 500.
Insiders selling. 7 insiders sold $40M of stock over the past 365 days and none bought (0% under pre-set trading plans).
Heavily shorted. 10.6% of the shares available to trade are sold short (10.2 days of average volume to cover).
Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share: -$0.48 against an average estimate of -$0.38: missed by 28.0%
Share reaction: +0.6% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report: November 12, 2026

Aura Biosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

1 day-1.8%
1 week-2.4%
1 month-1.0%
This year+10.6%
1 year-1.6%
5 years-66.2%
S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted): $-1.77

Growth

Share count change: +42.3%

Earnings

Last results: August 11, 2026
Next results (est.): November 10, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

August 11, 2026Results

Aura Biosciences, Inc. reported results; announced restructuring costs; announced a director or officer change; disclosed a material event

SEC 8-KRead source ↗
August 5, 2026Shareholder vote

Aura Biosciences, Inc. reported shareholder vote results

SEC 8-KRead source ↗
July 8, 2026Leadership

Aura Biosciences, Inc. announced a director or officer change

SEC 8-KRead source ↗

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Aura Biosciences, Inc. valuation models and calculator

No model value for Aura Biosciences, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Aura Biosciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.06 times a 4.5% equity risk premium.

Value per share by model
Model	Value per share	In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings.	—	Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years.	—	Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns.	—	Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable.	—	Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts.	~$0.1 ~$0.1–$0.6	Left out: out of range vs price (0.02x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld.	—	Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Aura Biosciences, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $0 for the quarter.

Analysts' consensus

Aura Biosciences, Inc.: consensus estimates
Fiscal year	EPS	Growth	Revenue	Growth
Current	−$1.67	+5%	—	0%
Next	−$1.52	+9%	$5m	0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +4.4% on 90 days ago. In the last 30 days, 1 analyst raised Aura Biosciences, Inc.'s forecast and 3 cut it.

Consensus EPS forecast Aura Biosciences, Inc., last 90 days

Average of analysts' published estimates (third-party data).

View chart data

Period	Current fiscal year	Next fiscal year
90 days ago	−$1.59	−$1.67
60 days ago	−$1.59	−$1.67
30 days ago	−$1.59	−$1.67
7 days ago	−$1.59	−$1.67
Now	−$1.67	−$1.52

Earnings against estimates

Aura Biosciences, Inc.: reported EPS against the consensus estimate
Quarter to	Estimate	Actual	Surprise
Jun 2026	−$0.38	−$0.48	−28.0%
Mar 2026	−$0.40	−$0.50	−25.8%
Dec 2025	−$0.43	−$0.37	+13.5%
Sept 2025	−$0.47	−$0.40	+14.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Oct 2026

Buy6100%

Hold00%

Sell00%

Monthly trend

Oct 2026156
Sep 2026156

Counts of recommendations published by analysts covering Aura Biosciences, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest: 10.6%
Days to cover: 10.19
Short interest, 1 month: +54%
Held by institutions: 96%
Held by insiders: 2.4%
Employees: 113

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Aura Biosciences, Inc.: yearly return, monthly win rate and worst fall against the S&P 500
Calendar year	2022	2023	2024	2025	2026 to date
Return
AURA	−38%	−16%	−7%	−34%	+11%
Industry peers (median)	−57%	−18%	−29%	−5%	−27%
S&P 500	−18%	+26%	+25%	+18%	+11%
Months that ended higher
AURA	50%	25%	42%	33%	55%
S&P 500	42%	67%	75%	75%	46%
Largest fall from a high during the year
AURA	−58%	−47%	−31%	−42%	−33%
S&P 500	−25%	−10%	−8%	−19%	−9%

Worst fall since October 29, 2021: 80% from November 16, 2021 to May 14, 2025. Getting back needed a 408% gain, and the shares have not yet recovered.

Price behaviour

52-week range: $4.97 – $8.90
From 52-week high: −32.2%
vs 50-day average: −9.3%
vs 200-day average: −10.3%
Volatility (1 year): 56%
Beta vs S&P 500: 0.96

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day: 7 up, 5 down
After a week: 4 up, 8 down
After a month: 3 up, 9 down

Aura Biosciences, Inc.: share-price change after each results release
Results released	Next day	S&P 500 next day	5 days	21 days
August 11, 2026	+0.6%	−0.1%	+6.0%	−9.2%
May 11, 2026	−5.6%	+0.1%	−11.1%	−27.1%
May 4, 2026	+27.0%	+0.4%	+16.8%	−1.9%
March 30, 2026	+6.7%	+2.6%	+5.7%	+7.3%
November 13, 2025	−0.7%	−1.7%	−3.9%	+13.6%
August 13, 2025	+0.9%	+0.4%	−8.2%	−11.0%
May 15, 2025	+21.4%	+1.1%	+21.2%	+30.6%
March 24, 2025	−5.6%	+2.0%	−21.9%	−23.2%
November 12, 2024	−7.3%	−0.3%	−19.9%	−24.2%
August 8, 2024	+1.3%	+2.8%	−0.1%	−1.8%
May 9, 2024	−1.1%	+0.7%	−2.6%	−2.0%
March 27, 2024	+2.9%	+0.8%	−6.0%	−5.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Dividends, buybacks and capital spending

Diluted share count: +42.3%; year over year

Who owns it

Funds buying and selling

Reported value: $698M
Institutions reporting: 146
Shares held vs prior quarter: ▲ 93.3%
Positions opened / closed: 36 / 14

94 bought 41 sold

Top buyers and sellers, Q2 2026: 94 institutions bought and 41 sold ; the biggest buyer was Tcg Crossover Management, LLC (+9.5M shares) and the biggest seller Matrix Capital Management Company, LP (−6.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager	Value	Shares	Share of 13F value	Shares QoQ
Tcg Crossover Management, LLC	$67.7M	9.5M	9.7%	New
Montanova Capital, LLC	$51.2M	7.2M	7.3%	▲ 64.8%
Frazier Life Sciences Management, L.P.	$50.4M	7.1M	7.2%	▲ 39.2%
Nantahala Capital Management, LLC	$41.9M	5.9M	6.0%	▲ 178.7%
Long Focus Capital Management, LLC	$36.3M	5.1M	5.2%	▲ 10.8%
Blackrock, Inc.	$33.4M	4.7M	4.8%	▲ 31.3%
Adage Capital Partners Gp, L.L.C.	$32.9M	4.6M	4.7%	▼ 4.9%
Caligan Partners LP	$30.5M	4.3M	4.4%	▲ 1769.9%
Vanguard Capital Management LLC	$29.1M	4.1M	4.2%	▲ 82.7%
Fcpm Iii Services B.V.	$28.8M	4.1M	4.1%	New
Orbimed Advisors LLC	$23.7M	3.3M	3.4%	New
Medicxi Ventures Management (Jersey) Ltd	$21.6M	3.0M	3.1%	0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Aura Biosciences, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart

Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $39.9M 11 trades by 7 insiders · 0% under pre-set plans

Net ▼ $39.9M net selling

Recent insider open-market transactions
Insider	Date	Trade	Shares	Price	Value
Gibney Anthony S See Remarks	June 16, 2026	Sell	12,824	$6.42	$82,330
Matrix Capital Management Company, Lp 10% owner	May 7, 2026	Sell	6,922,870	$5.64	$39M
Kilroy Conor See Remarks	April 16, 2026	Sell	11,738	$7.02	$82,401
De Los Pinos Elisabet See Remarks	February 17, 2026	Sell	47,648	$5.06	$241,099
Elazzouzi Amy Senior Vice President, Finance	February 17, 2026	Sell	8,549	$5.06	$43,258
Hopkins Janet Jill Chief Medical Officer	February 17, 2026	Sell	20,401	$5.06	$103,229
Plavsic Mark Chief Technology Officer	February 17, 2026	Sell	15,890	$5.05	$80,244
Kilroy Conor See Remarks	February 17, 2026	Sell	12,079	$5.05	$60,999
De Los Pinos Elisabet See Remarks	January 20, 2026	Sell	16,928	$4.86	$82,270
Elazzouzi Amy Senior Vice President, Finance	January 20, 2026	Sell	1,581	$4.86	$7,684
Hopkins Janet Jill Chief Medical Officer	November 17, 2025	Sell	17,109	$5.42	$92,731

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 10, 2026 estimated from the company's past filing pattern, not announced

August 11, 2026
May 11, 2026
May 4, 2026
March 30, 2026
November 13, 2025
August 13, 2025

Recent SEC filings

S-3 S-3 August 11, 2026
10-Q Quarterly report August 11, 2026
8-K Current report August 11, 2026
8-K Current report August 5, 2026
8-K Current report July 8, 2026
DEF 14A Proxy statement June 29, 2026
8-K Current report June 11, 2026
10-Q Quarterly report May 11, 2026

Data status

When each part of this page on Aura Biosciences, Inc. was last updated.

Data	Last updated	Source
Share price	November 2, 2026	Exchange closing prices
News and updates	October 31, 2026, 7:55pm ET	Company releases and SEC 8-K filings
Analyst estimates	October 31, 2026, 9:14am ET	Aggregated analyst estimates
Valuation and scores	November 3, 2026, 9:10am ET	Our models, from the filed figures

How we build and check these figures: methodology and data sources.

Aura Biosciences, Inc. in brief

What does Aura Biosciences, Inc. do?: Aura Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Aura Biosciences, Inc.'s stock ticker?: Aura Biosciences, Inc. trades under the ticker AURA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Aura Biosciences, Inc.'s largest institutional shareholders?: By value reported in 13F filings for June 30, 2026, the largest reported holders are Tcg Crossover Management, LLC, Montanova Capital, LLC and Frazier Life Sciences Management, L.P. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Aura Biosciences, Inc. stock?: Over the last 12 months, Aura Biosciences, Inc.'s directors and officers reported 0 open-market purchases and 11 sales on Form 4. The insider trading page charts every trade.
When is Aura Biosciences, Inc.'s next earnings date?: Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Aura Biosciences, Inc. announces its own schedule.